Next generation point-of-care diagnostic platform for the detection of biological agents down to the strain level

下一代护理点诊断平台，用于检测低至菌株水平的生物制剂

• 批准号: 131322
• 金额: $ 2.94万
• 依托单位: SOPHIMARK LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=131322
• 关键词: Next; generation; point; care; diagnostic

We are all exposed to biological agents which may cause us to be unwell, from infectious diseases transmitted from other people such as flu, to pathogens in contaminated food. While our immune systems cope well with many infections others may be life-threatening. Unfortunately the early symptoms of an illness do not necessarily pinpoint the cause and help to establish the potential severity. We address this by taking samples and subjecting them to diagnostic tests. Traditionally this testing has taken place in laboratories with qualified staff. However, this can be slow owing to the transport of the sample to the laboratory; in low-resource countries a laboratory simply may not be available. The solution lies in high-quality rapid test devices which can be run at home or 'in the field' without the need for special training. Sophimark Ltd has conceived of just such a next-generation technology and will use this public funding for a key development stage.

我们都接触到可能导致我们不适的生物制剂，从其他人传播的传染病（如流感）到受污染食物中的病原体。虽然我们的免疫系统可以很好地科普许多感染，但其他感染可能会危及生命。不幸的是，疾病的早期症状并不一定能确定病因，也不一定能帮助确定潜在的严重程度。我们通过取样并对它们进行诊断测试来解决这个问题。传统上，这种测试是在有合格工作人员的实验室进行的。然而，由于样本需要运送到实验室，这可能会很慢;在资源匮乏的国家，可能根本没有实验室。解决方案在于高质量的快速测试设备，可以在家中或“现场”运行，无需特殊培训。Sophimark有限公司已经设想了这样一种下一代技术，并将利用这笔公共资金进行关键的开发阶段。